See more : Meituan (MPNGY) Income Statement Analysis – Financial Results
Complete financial analysis of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- China Longevity Group Company Limited (1863.HK) Income Statement Analysis – Financial Results
- Israel Land Development – Urban Renewal Ltd (ILDR.TA) Income Statement Analysis – Financial Results
- Eminent Gold Corp. (EMNT.V) Income Statement Analysis – Financial Results
- Genes Tech Group Holdings Company Limited (8257.HK) Income Statement Analysis – Financial Results
- Fidelity China Special Situations PLC (FCSS.L) Income Statement Analysis – Financial Results
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ)
About Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions worldwide. The company offers patient monitoring and life support products, such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, endoscopes, and accessories, as well as emergency care, peri-operative care, critical care, and IT solutions. It also provides in-vitro diagnostics products, including hematology and chemistry analyzers and reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry products, and micro plate readers and washers, as well as coagulation, urinalysis, and microbiology solutions; medical imaging systems comprising ultrasound and radiology products; and veterinary products. The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.93B | 30.37B | 25.27B | 21.03B | 16.56B | 13.75B | 11.17B | 9.03B | 8.01B | 7.84B |
| Cost of Revenue | 11.82B | 10.89B | 8.84B | 7.37B | 5.76B | 4.60B | 3.68B | 3.20B | 3.03B | 2.87B |
| Gross Profit | 23.11B | 19.48B | 16.43B | 13.66B | 10.80B | 9.16B | 7.49B | 5.84B | 4.99B | 4.97B |
| Gross Profit Ratio | 66.16% | 64.15% | 65.01% | 64.97% | 65.24% | 66.57% | 67.03% | 64.62% | 62.22% | 63.43% |
| Research & Development | 3.43B | 2.92B | 2.52B | 1.87B | 1.47B | 1.27B | 1.02B | 989.67M | 988.23M | 944.07M |
| General & Administrative | 452.50M | 361.94M | 339.86M | 284.09M | 228.53M | 211.61M | 152.34M | 319.87M | 327.19M | 1.69B |
| Selling & Marketing | 5.70B | 4.80B | 4.00B | 3.61B | 3.61B | 3.20B | 2.73B | 2.40B | 2.18B | 2.09B |
| SG&A | 6.16B | 5.16B | 4.34B | 3.90B | 3.83B | 3.41B | 2.88B | 2.72B | 2.50B | 3.77B |
| Other Expenses | 453.25M | 726.58M | 472.97M | 354.47M | 363.22M | 99.13M | 51.78M | 302.61M | 128.11M | 248.54M |
| Operating Expenses | 10.04B | 8.81B | 7.34B | 6.12B | 5.66B | 4.98B | 4.21B | 4.31B | 4.01B | 3.85B |
| Cost & Expenses | 21.86B | 19.70B | 16.18B | 13.49B | 11.42B | 9.58B | 7.90B | 7.51B | 7.04B | 6.71B |
| Interest Income | 821.64M | 357.91M | 407.32M | 385.70M | 331.30M | 90.69M | 31.06M | 10.83M | 7.84M | 0.00 |
| Interest Expense | 85.90M | 10.69M | 8.63M | 70.87M | 79.79M | 42.50M | 80.99M | 67.27M | 39.71M | 97.37M |
| Depreciation & Amortization | 1.01B | 911.37M | 717.05M | 483.08M | 405.35M | 338.16M | 186.58M | 189.89M | 315.59M | -37.43M |
| EBITDA | 14.15B | 11.95B | 9.83B | 8.00B | 5.85B | 4.70B | 3.26B | 2.13B | 1.44B | 1.12B |
| EBITDA Ratio | 40.50% | 39.43% | 38.93% | 38.78% | 35.81% | 34.12% | 30.87% | 25.61% | 22.51% | 14.93% |
| Operating Income | 13.07B | 10.99B | 9.07B | 7.46B | 5.38B | 4.28B | 2.88B | 1.55B | 961.40M | 1.21B |
| Operating Income Ratio | 37.42% | 36.19% | 35.88% | 35.46% | 32.49% | 31.11% | 25.77% | 17.15% | 12.00% | 15.41% |
| Total Other Income/Expenses | -58.93M | -36.96M | -48.63M | -16.72M | -10.54M | -39.83M | 51.78M | 302.61M | 128.11M | 248.54M |
| Income Before Tax | 13.01B | 10.95B | 9.02B | 7.44B | 5.37B | 4.24B | 2.93B | 1.85B | 1.09B | 1.46B |
| Income Before Tax Ratio | 37.25% | 36.07% | 35.68% | 35.38% | 32.42% | 30.82% | 26.23% | 20.50% | 13.60% | 18.58% |
| Income Tax Expense | 1.43B | 1.34B | 1.01B | 778.84M | 683.44M | 512.58M | 330.18M | 239.37M | 149.00M | 61.28M |
| Net Income | 11.58B | 9.61B | 8.00B | 6.66B | 4.68B | 3.72B | 2.59B | 1.60B | 909.88M | 1.36B |
| Net Income Ratio | 33.16% | 31.64% | 31.66% | 31.66% | 28.27% | 27.04% | 23.17% | 17.72% | 11.35% | 17.35% |
| EPS | 9.56 | 7.94 | 6.59 | 5.48 | 3.85 | 3.34 | 2.37 | 1.61 | 0.98 | 1.47 |
| EPS Diluted | 9.56 | 7.94 | 6.59 | 5.48 | 3.85 | 3.34 | 2.37 | 1.61 | 0.98 | 1.47 |
| Weighted Avg Shares Out | 1.21B | 1.21B | 1.21B | 1.22B | 1.22B | 1.11B | 1.09B | 994.07M | 928.45M | 924.95M |
| Weighted Avg Shares Out (Dil) | 1.21B | 1.21B | 1.21B | 1.22B | 1.22B | 1.11B | 1.09B | 994.07M | 928.45M | 924.95M |
Source: https://incomestatements.info
Category: Stock Reports